TG Therapeutics
TGTX
365 hedge funds and large institutions have $3.5B invested in TG Therapeutics in 2026 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 137 increasing their positions, 106 reducing their positions, and 49 closing their positions.
39% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 49
29% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 106
14% more capital invested
Capital invested by funds: $3.07B → $3.5B (+$427M)
4% more funds holding
Funds holding: 352 → 365 (+13)
1.07% more ownership
Funds ownership: 64.96% → 66.03% (+1.1%)
0% more call options, than puts
Call options by funds: $82.4M | Put options by funds: $82.3M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$31.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$27.2M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$26.5M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$21.3M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$26.5M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$21.4M |
| 3 |
Man Group
London,
United Kingdom
|
-$17.9M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$16.7M |
| 5 |
Millennium Management
New York
|
-$16.5M |
TGTX Hedge Fund Activity: Q1 2026 in Review
365 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2026, worth a combined $3.5B — up 14% from $3.07B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new TGTX positions and 49 closed out — a net gain of 19 holders — while 137 added to existing stakes and 106 trimmed.
The largest buyer was Jane Street, adding an estimated $31.9M. The largest seller was Invesco, cutting an estimated $26.5M.
- 365 institutional investors held TG Therapeutics (TGTX) as of Q1 2026, up from 352 in Q4 2025.
- Funds reported $3.5B of TG Therapeutics stock for Q1 2026, up 14% quarter-over-quarter.
- 68 funds opened new TG Therapeutics positions in Q1 2026 and 49 closed out, a net change of +19 holders.
- The largest TG Therapeutics buyer in Q1 2026 was Jane Street, an estimated $31.9M added.
- The largest TG Therapeutics seller in Q1 2026 was Invesco, an estimated $26.5M sold.
Based on aggregated 13F filings for Q1 2026.